Robyn K. Fuchs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robyn K. Fuchs has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
B. Keck
Procter and Gamble Pharmaceuticals
2 shared publications- Charles H. Turner
Biomechanics and Biomaterials Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
2 shared publications D. B. Burr
Indiana University
2 shared publicationsD. McClenathan
Procter and Gamble Pharmaceuticals
2 shared publicationsK. W. Condon
Indiana University
2 shared publicationsL. M. Miller
Brookhaven National Laboratory
2 shared publications
Latest Publications
- 10 February 2018
- Published by Springer Nature
- p. 53-76
Physical Activity to Promote Bone Health in Adolescents
- 10 February 2018
- Published by Springer Nature
- p. 53-76
Physical Activity to Promote Bone Health in Adolescents
- 1 May 2015
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 47 (5S) , 619
Progressive Skeletal Benefits Of Exercise When Young
- 1 May 2015
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 47 (5S) , 619
Progressive Skeletal Benefits Of Exercise When Young
- Open Access
- 1 July 2014
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 94 (7) , 907-920
Research Summit III Proceedings on Dosing in Children With an Injured Brain or Cerebral Palsy: Executive Summary
Children with brain injuries or cerebral palsy (CP) comprise a large percentage of pediatric clients served by physical therapists. There is no consensus on wha
- 1 July 2014
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 94 (7) , 907-920
Open AccessResearch Summit III Proceedings on Dosing in Children With an Injured Brain or Cerebral Palsy: Executive Summary
Children with brain injuries or cerebral palsy (CP) comprise a large percentage of pediatric clients served by physical therapists. There is no consensus on wha
- 1 January 2009
- Published by Elsevier
Contributor contact details
- Open Access
- 1 October 2008
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 23 (10) , 1689-1697
Recovery of Trabecular and Cortical Bone Turnover After Discontinuation of Risedronate and Alendronate Therapy in Ovariectomized Rats
Alendronate (ALN) and risedronate (RIS) are bisphosphonates effective in reducing bone loss and fractures associated with postmenopausal osteoporosis. However, it is uncertain how long it takes bone turnover to be re‐established after treatment withdrawal, and whether this differs between the two drugs. The objective of this study was to determine the time required to re‐establish normal bone turnover after the discontinuation of ALN and RIS treatment in an animal model of estrogen‐deficiency osteoporosis. Two hundred ten, 6‐mo‐old female Sprague‐Dawley rats were ovariectomized and 6 wk later were randomized into baseline controls (n = 10) and four treatment groups (n = 50/group): vehicle‐treated controls (CON; 0.3 ml sterile water), ALN (2.4 μg/kg), low‐dose RIS (RIS low; 1.2 μg/kg), and high‐dose RIS (RIS high; 2.4 μg/kg). Treatments were administered 3 times/wk by subcutaneous injection. Baseline controls were killed at the initiation of treatment. Other groups were treated for 8 wk, and subgroups (n = 10/ treatment group) were killed 0, 4, 8, 12, and 16 wk after treatment was withdrawn. Static and dynamic histological analyses were performed for cortical (tibial diaphysis) and trabecular (proximal tibia and L4 vertebrae) bone. DXA and mechanical testing was performed on the L5 vertebra. After 8 wk of treatment, trabecular bone turnover rates were significantly suppressed in all drug‐treated animals. Trabecular bone formation rate (BFR/BS) remained significantly lower than vehicle in bisphosphonate‐treated animals through 12 wk. Sixteen weeks after treatment withdrawal, trabecular BFR/BS in the proximal tibia was re‐established in animals treated with RIS but not in animals treated with ALN compared with controls. BMD of the fifth lumbar vertebra remained significantly higher than controls 16 wk after treatment withdrawal in ALN‐treated animals but not in RIS‐treated animals. Despite reductions in BMD and increases in bone turnover, ultimate force of the fifth lumbar vertebra remained significantly higher in all drug‐treated animals through 16 wk after withdrawal.
- 1 October 2008
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 23 (10) , 1689-1697
Open AccessRecovery of Trabecular and Cortical Bone Turnover After Discontinuation of Risedronate and Alendronate Therapy in Ovariectomized Rats
Alendronate (ALN) and risedronate (RIS) are bisphosphonates effective in reducing bone loss and fractures associated with postmenopausal osteoporosis. However, it is uncertain how long it takes bone turnover to be re‐established after treatment withdrawal, and whether this differs between the two drugs. The objective of this study was to determine the time required to re‐establish normal bone turnover after the discontinuation of ALN and RIS treatment in an animal model of estrogen‐deficiency osteoporosis. Two hundred ten, 6‐mo‐old female Sprague‐Dawley rats were ovariectomized and 6 wk later were randomized into baseline controls (n = 10) and four treatment groups (n = 50/group): vehicle‐treated controls (CON; 0.3 ml sterile water), ALN (2.4 μg/kg), low‐dose RIS (RIS low; 1.2 μg/kg), and high‐dose RIS (RIS high; 2.4 μg/kg). Treatments were administered 3 times/wk by subcutaneous injection. Baseline controls were killed at the initiation of treatment. Other groups were treated for 8 wk, and subgroups (n = 10/ treatment group) were killed 0, 4, 8, 12, and 16 wk after treatment was withdrawn. Static and dynamic histological analyses were performed for cortical (tibial diaphysis) and trabecular (proximal tibia and L4 vertebrae) bone. DXA and mechanical testing was performed on the L5 vertebra. After 8 wk of treatment, trabecular bone turnover rates were significantly suppressed in all drug‐treated animals. Trabecular bone formation rate (BFR/BS) remained significantly lower than vehicle in bisphosphonate‐treated animals through 12 wk. Sixteen weeks after treatment withdrawal, trabecular BFR/BS in the proximal tibia was re‐established in animals treated with RIS but not in animals treated with ALN compared with controls. BMD of the fifth lumbar vertebra remained significantly higher than controls 16 wk after treatment withdrawal in ALN‐treated animals but not in RIS‐treated animals. Despite reductions in BMD and increases in bone turnover, ultimate force of the fifth lumbar vertebra remained significantly higher in all drug‐treated animals through 16 wk after withdrawal.
- 16 September 2008
- Published by Springer Nature in Osteoporosis International
- Vol. 19 (12) , 1815-1817
Calculating clinically relevant drug doses to use in animal studies
- 16 September 2008
- Published by Springer Nature in Osteoporosis International
- Vol. 19 (12) , 1815-1817
Calculating clinically relevant drug doses to use in animal studies
- 14 June 2008
- Published by Springer Nature in Clinical & Translational Metabolism
- Vol. 6 (1) , 37-45
Combination Therapy Using Exercise and Pharmaceutical Agents to Optimize Bone Health
- 14 June 2008
- Published by Springer Nature in Clinical & Translational Metabolism
- Vol. 6 (1) , 37-45
Combination Therapy Using Exercise and Pharmaceutical Agents to Optimize Bone Health
- 3 April 2008
- Published by Springer Nature in Osteoporosis International
- Vol. 19 (9) , 1331-1341
Strontium ranelate does not stimulate bone formation in ovariectomized rats
Strontium ranelate (SrR) is suggested to function as a dual-acting agent in the treatment of postmenopausal osteoporosis with anti-resorptive and anabolic skeletal benefits. We evaluated the effects of SrR on the skeleton in ovariectomized (OVX) rats and evaluated the influence of dietary calcium.
- 3 April 2008
- Published by Springer Nature in Osteoporosis International
- Vol. 19 (9) , 1331-1341
Strontium ranelate does not stimulate bone formation in ovariectomized rats
Strontium ranelate (SrR) is suggested to function as a dual-acting agent in the treatment of postmenopausal osteoporosis with anti-resorptive and anabolic skeletal benefits. We evaluated the effects of SrR on the skeleton in ovariectomized (OVX) rats and evaluated the influence of dietary calcium.
- Top Cited PapersOpen Access
- 24 October 2006
- Published by Springer Nature in Breast Cancer Research
- Vol. 8 (5) , 1-13
CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis
Introduction: A subpopulation (CD44+/CD24-) of breast cancer cells has been reported to have stem/progenitor cell properties. The aim of this study was to investigate whether this subpopulation of cancer cells has the unique ability to invade, home, and proliferate at sites of metastasis. Methods: CD44 and CD24 expression was determined by flow cytometry. Northern blotting was used to determine the expression of proinvasive and 'bone and lung metastasis signature' genes. A matrigel invasion assay and intracardiac inoculation into nude mice were used to evaluate invasion, and homing and proliferation at sites of metastasis, respectively. Results: Five among 13 breast cancer cell lines examined (MDA-MB-231, MDA-MB-436, Hs578T, SUM1315, and HBL-100) contained a higher percentage (>30%) of CD44+/CD24- cells. Cell lines with high CD44+/CD24- cell numbers express basal/mesenchymal or myoepithelial but not luminal markers. Expression levels of proinvasive genes (IL-1α, IL-6, IL-8, and urokinase plasminogen activator [UPA]) were higher in cell lines with a significant CD44+/CD24- population than in other cell lines. Among the CD44+/CD24--positive cell lines, MDA-MB-231 has the unique property of expressing a broad range of genes that favor bone and lung metastasis. Consistent with previous studies in nude mice, cell lines with CD44+/CD24- subpopulation were more invasive than other cell lines. However, only a subset of CD44+/CD24--positive cell lines was able to home and proliferate in lungs. Conclusion: Breast cancer cells with CD44+/CD24- subpopulation express higher levels of proinvasive genes and have highly invasive properties. However, this phenotype is not sufficient to predict capacity for pulmonary metastasis.
- 24 October 2006
- Published by Springer Nature in Breast Cancer Research
- Vol. 8 (5) , 1-13
Top Cited PapersOpen AccessCD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis
Introduction: A subpopulation (CD44+/CD24-) of breast cancer cells has been reported to have stem/progenitor cell properties. The aim of this study was to investigate whether this subpopulation of cancer cells has the unique ability to invade, home, and proliferate at sites of metastasis. Methods: CD44 and CD24 expression was determined by flow cytometry. Northern blotting was used to determine the expression of proinvasive and 'bone and lung metastasis signature' genes. A matrigel invasion assay and intracardiac inoculation into nude mice were used to evaluate invasion, and homing and proliferation at sites of metastasis, respectively. Results: Five among 13 breast cancer cell lines examined (MDA-MB-231, MDA-MB-436, Hs578T, SUM1315, and HBL-100) contained a higher percentage (>30%) of CD44+/CD24- cells. Cell lines with high CD44+/CD24- cell numbers express basal/mesenchymal or myoepithelial but not luminal markers. Expression levels of proinvasive genes (IL-1α, IL-6, IL-8, and urokinase plasminogen activator [UPA]) were higher in cell lines with a significant CD44+/CD24- population than in other cell lines. Among the CD44+/CD24--positive cell lines, MDA-MB-231 has the unique property of expressing a broad range of genes that favor bone and lung metastasis. Consistent with previous studies in nude mice, cell lines with CD44+/CD24- subpopulation were more invasive than other cell lines. However, only a subset of CD44+/CD24--positive cell lines was able to home and proliferate in lungs. Conclusion: Breast cancer cells with CD44+/CD24- subpopulation express higher levels of proinvasive genes and have highly invasive properties. However, this phenotype is not sufficient to predict capacity for pulmonary metastasis.